Daxor (DXR) Competitors $10.60 -0.01 (-0.09%) As of 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DXR vs. SGHT, INGN, PROF, TLSI, ELMD, KRMD, LNSR, PDEX, RCEL, and LAKEShould you be buying Daxor stock or one of its competitors? The main competitors of Daxor include Sight Sciences (SGHT), Inogen (INGN), Profound Medical (PROF), TriSalus Life Sciences (TLSI), Electromed (ELMD), KORU Medical Systems (KRMD), LENSAR (LNSR), Pro-Dex (PDEX), Avita Medical (RCEL), and Lakeland Industries (LAKE). These companies are all part of the "medical equipment" industry. Daxor vs. Its Competitors Sight Sciences Inogen Profound Medical TriSalus Life Sciences Electromed KORU Medical Systems LENSAR Pro-Dex Avita Medical Lakeland Industries Daxor (NASDAQ:DXR) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Do insiders & institutionals believe in DXR or SGHT? 1.3% of Daxor shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 59.5% of Daxor shares are owned by insiders. Comparatively, 30.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is DXR or SGHT more profitable? Daxor has a net margin of 0.00% compared to Sight Sciences' net margin of -64.23%. Daxor's return on equity of 0.00% beat Sight Sciences' return on equity.Company Net Margins Return on Equity Return on Assets DaxorN/A N/A N/A Sight Sciences -64.23%-59.38%-36.43% Which has more risk and volatility, DXR or SGHT? Daxor has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500. Do analysts rate DXR or SGHT? Daxor currently has a consensus target price of $25.00, indicating a potential upside of 135.85%. Sight Sciences has a consensus target price of $4.27, indicating a potential upside of 1.59%. Given Daxor's stronger consensus rating and higher possible upside, analysts clearly believe Daxor is more favorable than Sight Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sight Sciences 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43 Which has better valuation and earnings, DXR or SGHT? Daxor has higher earnings, but lower revenue than Sight Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaxorN/AN/AN/AN/AN/ASight Sciences$79.87M2.75-$51.51M-$0.96-4.38 Does the media prefer DXR or SGHT? In the previous week, Sight Sciences had 4 more articles in the media than Daxor. MarketBeat recorded 8 mentions for Sight Sciences and 4 mentions for Daxor. Sight Sciences' average media sentiment score of 0.77 beat Daxor's score of 0.72 indicating that Sight Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sight Sciences 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDaxor and Sight Sciences tied by winning 6 of the 12 factors compared between the two stocks. Get Daxor News Delivered to You Automatically Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXR vs. The Competition Export to ExcelMetricDaxorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.30M$4.04B$5.68B$9.80BDividend YieldN/A1.25%4.59%4.07%P/E RatioN/A26.2530.6825.54Price / SalesN/A24.67463.80116.04Price / CashN/A26.2938.2159.48Price / BookN/A2.798.996.13Net IncomeN/A$189.47M$3.25B$264.89M7 Day Performance5.79%4.14%4.76%2.66%1 Month Performance11.58%11.71%6.72%3.05%1 Year Performance17.78%8.82%30.51%25.05% Daxor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXRDaxor4.073 of 5 stars$10.60-0.1%$25.00+135.8%+21.8%$51.30MN/A0.0037Short Interest ↓Gap UpSGHTSight Sciences1.6617 of 5 stars$3.49+0.6%$3.93+12.7%-26.6%$179.38M$79.87M-3.56210INGNInogen4.3843 of 5 stars$6.33-3.2%$11.00+73.8%-37.0%$175.84M$335.70M-5.501,030News CoveragePROFProfound Medical2.2427 of 5 stars$5.58-1.9%$11.00+97.1%-40.5%$171.01M$10.68M-4.57150Trending NewsEarnings ReportGap DownTLSITriSalus Life Sciences3.0774 of 5 stars$4.21+0.2%$10.75+155.3%-33.7%$158.92M$29.43M-3.76106News CoverageEarnings ReportAnalyst RevisionELMDElectromed1.3408 of 5 stars$18.61-0.1%$33.50+80.0%+33.6%$156.06M$61.44M24.81160KRMDKORU Medical Systems2.0211 of 5 stars$3.28-3.0%$4.63+41.0%+78.4%$155.96M$33.65M-29.8280Positive NewsLNSRLENSAR0.6732 of 5 stars$13.04+0.8%$15.00+15.0%+211.7%$152.59M$53.49M-2.69110News CoveragePositive NewsPDEXPro-Dex3.1263 of 5 stars$45.09-1.4%$56.00+24.2%+118.1%$149.05M$53.84M16.10140RCELAvita Medical1.6212 of 5 stars$5.28-1.3%$16.50+212.5%-35.5%$141.43M$64.25M-2.41130Analyst RevisionLAKELakeland Industries4.7862 of 5 stars$14.09+2.4%$26.00+84.5%-34.8%$130.92M$167.21M-4.682,100Trending NewsEarnings ReportAnalyst UpgradeOptions VolumeGap Up Related Companies and Tools Related Companies Sight Sciences Alternatives Inogen Alternatives Profound Medical Alternatives TriSalus Life Sciences Alternatives Electromed Alternatives KORU Medical Systems Alternatives LENSAR Alternatives Pro-Dex Alternatives Avita Medical Alternatives Lakeland Industries Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DXR) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access